HealthKnowItAllHuman Genome shares plunge on study resultsForbesAP , 03.09.09, 12:10 PM EDT Shares of drug developer Human Genome Sciences Inc. were nearly cut in half Monday as Wall Street expressed disappointment over the company's latest study results for the developing hepatitis C drug Albuferon.Human Genome Sciences drug succeeds in trial Bizjournals.comPositive Results For Human Genome Experimental Hepatitis C Drug HealthKnowItAllTheStreet.com - FierceBiotech - MSNBC - PR Newswire (press release)all 41 news articles